Tilray Issues 1.6M Shares to Fund Lyphe Buyout, Debt Reduction

Share Issuance Details

Tilray issued exactly 1,600,000 common shares at an undisclosed price in a private placement completed June 9, 2026. The company disclosed the transaction in a Form 6-K filed with the Securities and Exchange Commission on June 10. The filing didn't specify the per-share price or the gross proceeds, but the shares were issued to fund two stated purposes: finalizing the Lyphe Group acquisition and paying down existing debt.

The issuance represents approximately 0.15% dilution to Tilray's outstanding share count, which stood at roughly 1.05 billion shares as of the company's May 2026 earnings call. TLRY closed at $1.87 on June 10. That's up from $1.81 the prior session, extending a modest two-day gain.

Lyphe Group Acquisition Background

Tilray announced its agreement to acquire UK-based medical cannabis distributor Lyphe Group in March 2026 for an undisclosed sum. Lyphe operates a network of specialty clinics and an e-commerce platform serving more than 30,000 registered patients across the United Kingdom and Germany. The deal was structured as a stock-and-cash transaction, with regulatory approvals pending at the time of announcement.

The June 9 share issuance suggests the acquisition has cleared final regulatory hurdles, though Tilray hasn't issued a formal closing statement. Lyphe's patient base and European distribution footprint align with Tilray's stated strategy to expand its medical cannabis operations outside North America, where the company faces margin pressure from oversupply and regulatory delays.

Debt Reduction Strategy

Tilray carried $393 million in long-term debt as of its fiscal Q3 2026 balance sheet, down from $441 million a year earlier. The company has prioritized debt reduction since CEO Irwin Simon took the helm in 2020, using a combination of asset sales, equity raises, and free cash flow to chip away at borrowings inherited from the 2019 Aphria reverse merger.

The dual-purpose equity raise—funding an acquisition while simultaneously paying down debt—reflects Tilray's balancing act between growth and deleveraging. The company generated $47 million in adjusted EBITDA in fiscal Q3 2026 but remains unprofitable on a GAAP basis, posting a net loss of $68 million in the quarter. For context on Tilray's acquisition history and capital structure, see the CannIntel topic hub on Tilray Acquisitions.

Market Reaction and Outlook

TLRY shares have gained 6.1% over the past two trading sessions, though the stock remains down 22% year-to-date. The rally follows a broader uptick in cannabis equities tied to renewed speculation over federal rescheduling in the United States, though no concrete timeline has emerged from the Drug Enforcement Administration.

Tilray's diversified revenue model—spanning Canadian cannabis, U.S. craft beer, European medical distribution, and wellness products—has insulated the company from single-market volatility but complicated its equity story. Analysts at Canaccord Genuity maintain a Hold rating on TLRY with a $2.00 price target, citing execution risk in integrating multiple acquisitions.

Watch for Tilray's fiscal Q4 2026 earnings, expected in late July. Management will likely detail the Lyphe integration timeline and updated debt metrics then.